Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoporosis | 6 | 2023 | 224 | 1.930 |
Why?
|
| Bone Neoplasms | 2 | 2017 | 191 | 0.580 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2015 | 26 | 0.570 |
Why?
|
| Aromatase Inhibitors | 2 | 2015 | 49 | 0.560 |
Why?
|
| Physicians | 1 | 2023 | 765 | 0.480 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 271 | 0.440 |
Why?
|
| Prostatic Neoplasms | 1 | 2020 | 913 | 0.430 |
Why?
|
| Bone and Bones | 1 | 2013 | 277 | 0.360 |
Why?
|
| Breast Neoplasms | 3 | 2015 | 1846 | 0.300 |
Why?
|
| Arthropathy, Neurogenic | 1 | 2007 | 4 | 0.280 |
Why?
|
| Diabetes Complications | 1 | 2007 | 208 | 0.240 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2023 | 43 | 0.200 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 4598 | 0.170 |
Why?
|
| Androgen Antagonists | 1 | 2020 | 69 | 0.170 |
Why?
|
| Family Practice | 1 | 2023 | 426 | 0.160 |
Why?
|
| Aged | 6 | 2020 | 18973 | 0.150 |
Why?
|
| Hyperparathyroidism | 1 | 2017 | 12 | 0.140 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2023 | 1175 | 0.140 |
Why?
|
| Betacoronavirus | 1 | 2020 | 247 | 0.140 |
Why?
|
| RNA Splice Sites | 1 | 2017 | 33 | 0.140 |
Why?
|
| Kidney Transplantation | 1 | 2023 | 538 | 0.140 |
Why?
|
| Hyperglycemia | 1 | 2020 | 292 | 0.140 |
Why?
|
| Bone Density Conservation Agents | 2 | 2019 | 62 | 0.140 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2017 | 34 | 0.140 |
Why?
|
| Abdominal Fat | 1 | 2017 | 39 | 0.140 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2017 | 29 | 0.140 |
Why?
|
| Carcinoma, Papillary | 1 | 2017 | 74 | 0.130 |
Why?
|
| Diphosphonates | 2 | 2013 | 51 | 0.130 |
Why?
|
| Point Mutation | 1 | 2017 | 216 | 0.130 |
Why?
|
| Bone Density | 2 | 2017 | 432 | 0.130 |
Why?
|
| SEER Program | 1 | 2017 | 195 | 0.130 |
Why?
|
| Hand Strength | 1 | 2016 | 97 | 0.120 |
Why?
|
| Muscle Weakness | 1 | 2016 | 81 | 0.120 |
Why?
|
| Carcinoma | 1 | 2017 | 198 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 334 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 326 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 283 | 0.120 |
Why?
|
| Osteochondroma | 1 | 2015 | 7 | 0.120 |
Why?
|
| Humans | 16 | 2023 | 114080 | 0.120 |
Why?
|
| Toes | 1 | 2015 | 26 | 0.120 |
Why?
|
| Middle Aged | 8 | 2017 | 26621 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 138 | 0.120 |
Why?
|
| Mass Screening | 1 | 2020 | 979 | 0.110 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 1080 | 0.110 |
Why?
|
| Adiposity | 1 | 2017 | 458 | 0.100 |
Why?
|
| Male | 9 | 2020 | 55420 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 6307 | 0.100 |
Why?
|
| Cartilage, Articular | 1 | 2015 | 286 | 0.090 |
Why?
|
| Survival Rate | 1 | 2013 | 1638 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2023 | 2087 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1837 | 0.080 |
Why?
|
| Adult | 5 | 2017 | 30395 | 0.080 |
Why?
|
| Potassium | 1 | 2009 | 127 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 898 | 0.070 |
Why?
|
| Blood Sedimentation | 1 | 2007 | 32 | 0.070 |
Why?
|
| United States | 1 | 2023 | 12144 | 0.070 |
Why?
|
| Exercise | 1 | 2017 | 1641 | 0.070 |
Why?
|
| Cellulitis | 1 | 2007 | 45 | 0.070 |
Why?
|
| Coronary Angiography | 1 | 2009 | 308 | 0.070 |
Why?
|
| Hypolipidemic Agents | 1 | 2007 | 86 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2007 | 88 | 0.070 |
Why?
|
| Leukocyte Count | 1 | 2007 | 292 | 0.070 |
Why?
|
| Edema | 1 | 2007 | 119 | 0.070 |
Why?
|
| Foot | 1 | 2007 | 103 | 0.070 |
Why?
|
| Female | 6 | 2017 | 59349 | 0.060 |
Why?
|
| Radiography | 1 | 2007 | 803 | 0.060 |
Why?
|
| Risk Factors | 2 | 2016 | 8612 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 428 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2007 | 373 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2009 | 611 | 0.050 |
Why?
|
| Quality of Life | 1 | 2013 | 2346 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2007 | 1331 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 2007 | 367 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 1875 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 3039 | 0.050 |
Why?
|
| Hypertension | 1 | 2007 | 1052 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2020 | 614 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2016 | 122 | 0.030 |
Why?
|
| Anthropometry | 1 | 2016 | 183 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2023 | 1011 | 0.030 |
Why?
|
| Income | 1 | 2016 | 167 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 1311 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1381 | 0.020 |
Why?
|
| Imidazoles | 1 | 2012 | 203 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2020 | 1827 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 1707 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2017 | 1957 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2886 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2023 | 12521 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2009 | 342 | 0.020 |
Why?
|
| Logistic Models | 1 | 2009 | 1830 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 932 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 10459 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2007 | 1531 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 4885 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2007 | 9051 | 0.010 |
Why?
|